United
Kingdom chronic obstructive pulmonary disease treatment market is anticipated
to witness impressive growth during the forecast period. It can be
ascribed to the growing demand for effective medications because it gives some
health benefits such as improved lung function, reduced exacerbations, enhanced
exercise capacity and reduced mortality risk along with growing demand for inhalation
devices as daily routine for health benefits. Also, increasing demand for integrated
care, disease management, and digital health solutions additives along with
growing demand for effective medications and personalized treatment such as bronchodilators,
inhaled corticosteroids, combination medications, diagnosis and disease
severity, inhaler device selection, and lifestyle modifications is expected to
create a lucrative growth of United Kingdom chronic obstructive pulmonary
disease treatment market during the forecast period.
According to
National Institutes of Health Each year, pneumonia is diagnosed in about 220,000
persons. Although some people acquire several diagnoses in one year, Also
focused on the number of people who received a diagnosis rather than the number
of cases. There is a high demand for effective medications that can alleviate
symptoms, improve lung function, and reduce exacerbations in chronic obstructive pulmonary
disease (COPD) patients. Bronchodilators, corticosteroids, and combination
therapies are commonly prescribed to manage chronic obstructive pulmonary disease (COPD).
Effective chronic
obstructive pulmonary disease (COPD) medications help alleviate symptoms such as
shortness of breath, coughing, and wheezing. By reducing airway inflammation
and opening the air passages, medications can provide relief and improve the
overall quality of life for chronic
obstructive pulmonary disease (COPD) patients may contribute to United Kingdom chronic obstructive pulmonary
disease treatment market growth.
Smoking and Pollution Drive the Market Growth
Smoking
and pollution are significantly causing chronic obstructive pulmonary disease
(COPD) treatment in the United Kingdom cigarette smoking is the main
contributor of COPD. Only 10% of cases are non-smokers, although 10–20% of
smokers will eventually get the disease 90% of cases of chronic obstructive
pulmonary disease (COPD) is because of smoking. Smoking is the leading
cause of chronic obstructive pulmonary disease (COPD) in the UK and globally.
The majority of chronic obstructive pulmonary disease (COPD) cases are directly
linked to smoking cigarettes or other forms of tobacco use. In United
Kingdom 13.3% of people 18 year and over smoked cigarettes which is 6.6 million
peoples in the population. Smoking damages the airways and lung tissue,
leading to inflammation, narrowing of the airways, and reduced lung function.
Due to the strong association between smoking and chronic obstructive pulmonary
disease (COPD), smoking cessation is a primary focus in COPD treatment.
Healthcare providers emphasize the importance of quitting smoking to slow
disease progression, alleviate symptoms, and reduce the risk of exacerbations.
Smoking cessation interventions, such as counseling, nicotine replacement
therapies, and medication assistance, are incorporated into chronic obstructive
pulmonary disease (COPD) treatment plans. The MPOWER package is a set of
evidence-based strategies developed by the WHO to support countries in
implementing effective tobacco control measures. MPOWER stands for:
Monitor
tobacco use and prevention policies, protect people from tobacco smoke, offer
to help to quit tobacco use, warn about the dangers of tobacco, enforce bans on
tobacco advertising, promotion, and sponsorship, and raise taxes on tobacco
products.
By
implementing these strategies, the MPOWER package aims to reduce tobacco use,
encourage smoking cessation, and protect individuals from the harms of smoking.
Exposure
to environmental pollutants, such as particulate matter, industrial emissions,
and outdoor air pollution, can contribute to the development and exacerbation
of chronic obstructive pulmonary disease (COPD). Poor air quality is a concern
in certain regions of the UK, In London there are more than 500000 people
who live with asthma with US AQI 68. especially in urban areas and
locations with high industrial activity. This may anticipate in the growth of
United Kingdom chronic obstructive pulmonary disease treatment market.
Growing COPD Prevalence Promise the Growth of Market
The
growing prevalence of chronic obstructive pulmonary disease (COPD) in the
United Kingdom is a significant driver for the COPD treatment market. As
Chronic Obstructive Pulmonary Disease (COPD) becomes more prevalent, there is
an increasing demand for effective treatments and therapies to manage the
disease. According to NHS Digital data, 1.9% of the population in England
had a COPD diagnosis in 2020–21, which is approximately 1.17 million people. The
rising prevalence of chronic obstructive pulmonary disease (COPD) means a
larger patient pool requiring treatment. Around 2% of the whole population, in
which, 4.5% of people are over 40 years aged. Chronic obstructive pulmonary
disease (COPD) is a chronic and progressive disease, and as the population ages
and risk factors such as smoking and environmental pollution persist, the
number of individuals with chronic obstructive pulmonary disease (COPD)
continues to grow. This larger patient pool creates a demand for chronic
obstructive pulmonary disease (COPD) treatments, driving the United Kingdom chronic
obstructive pulmonary disease treatment market.
With
the growing chronic obstructive pulmonary disease (COPD) prevalence, there is a
need for diverse treatment and management options to address the varying needs
of chronic obstructive pulmonary disease (COPD) patients. This drives research
and development efforts to innovate and introduce new medications, inhalation
devices, and therapeutic approaches. The availability of a wider range of
treatment options allows healthcare providers to personalize care based on
individual patient needs and preferences, which is driving the growth of United
Kingdom chronic obstructive pulmonary disease treatment market.
Download Free Sample Report
Increasing Awareness and Diagnosis
Increasing
awareness and diagnosis of chronic obstructive pulmonary disease (COPD) in the
United Kingdom have a positive impact on the COPD treatment market. Improved
awareness of chronic obstructive pulmonary disease (COPD) symptoms and risk
factors encourages individuals to seek medical attention earlier, leading to
earlier diagnosis and intervention. Timely diagnosis allows healthcare
providers to initiate appropriate treatments and interventions, which can slow
disease progression, improve symptom management, and enhance patient outcomes.
Increased awareness and early diagnosis drive the demand for United Kingdom chronic
obstructive pulmonary disease treatment market. Increasing awareness about COPD
raises public consciousness about the disease and its impact on individuals'
health. 1,170,437 individuals were diagnosed with chronic obstructive
pulmonary disease (COPD), making it the 1.93% national prevalence. As a
result, more individuals who were previously undiagnosed or underdiagnosed seek
medical evaluation, leading to a larger patient pool. This expanding patient
pool creates a greater demand for COPD treatments, driving the growth of the
United Kingdom chronic obstructive pulmonary disease treatment market.
Recent Development
In 2022, Affinivax,
Inc., a clinical-stage biopharmaceutical company, will be acquired by GSK for
US$2.1 billion, plus up to US$1.2 billion in potential milestone payments. The
most innovative vaccinations in this new class are next-generation pneumococcal
vaccines, which are being developed by Affinivax.
In 2018, The consumer health operations of
GlaxoSmithKline plc and Pfizer Inc will be united into a new, globally
recognised joint venture with combined sales of about USD9.8 billion (USD12.7
billion). In the joint venture, GSK will hold a 68% majority controlling equity
interest, while Pfizer will hold a 32% equity stake.
In October 2021,
GSK has unveiled plans for a new consumer healthcare company's UK headquarters.
In addition to its long-term plan for the GSK headquarters, GSK unveiled
designs for a significant new UK-based headquarters and worldwide campus for
the new Consumer Healthcare company following its separation in 2022.
Market Segmentation
The
United Kingdom chronic obstructive pulmonary disease treatment market can be segmented
by Treatment Type, Type, Distribution Channel and region. Based on Treatment
Type, the market can be segmented into Combination
Therapy, Bronchodilators, Corticosteroids, Phosphodiester Type 4 Inhibitor,
Mucokinetics, and Others. Based on Type, the market can be segmented into Chronic
Bronchitis, and Emphysema. Based on Distribution Channel, the market can be
grouped into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
Based on region, the market can be grouped into Scotland, Southeast, London,
Southwest, Yorkshire, and East Midlands
Market Players
GlaxoSmithKline
(GSK) PLC, AstraZeneca Ltd, Boehringer Ingelheim GmbH, Novartis Ltd, Teva
Pharmaceutical Industries Ltd., Orion Pharma Ltd, and Vectura Group Ltd/United
Kingdom. are some of the leading players operating in the United Kingdom chronic
obstructive pulmonary disease treatment market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 –
2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024
– 2028
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
Scotland, Southeast, London, Southwest, Yorkshire, East
Midlands
|
|
Regional
scope
|
Scotland,
South-East, London, South-West, Yorkshire & Humberside, and East Midlands
|
|
Key
companies profiled
|
GlaxoSmithKline (GSK) PLC, AstraZeneca Ltd, Boehringer
Ingelheim GmbH, Novartis Ltd, Teva Pharmaceutical Industries Ltd., Orion
Pharma Ltd, Vectura Group Ltd/United Kingdom.
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through
Email (We can also provide the editable version of the report in PPT/Word
format on special request)
|
Report
Scope:
In this
report, the United Kingdom chronic obstructive pulmonary disease treatment market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- United Kingdom Chronic Obstructive
Pulmonary Disease Treatment Market, By Treatment Type:
o Combination Therapy
o Bronchodilators
o Corticosteroids
o Phosphodiester Type 4 Inhibitor
o Mucokinetics
o Others
- United Kingdom Chronic Obstructive
Pulmonary Disease Treatment Market, By Type:
o Chronic Bronchitis
o Emphysema
- United Kingdom Chronic Obstructive
Pulmonary Disease Treatment Market,
By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
- United Kingdom Chronic Obstructive
Pulmonary Disease Treatment Market, By Region:
o
Scotland
o
South-East
o
London
o
South-West
o
Yorkshire & Humberside
o
East Midlands
Competitive
Landscape
Company
Profiles: Detailed analysis of the major companies
present United Kingdom chronic obstructive pulmonary disease treatment market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
United
Kingdom chronic obstructive pulmonary disease treatment market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]